1. What Is the Vascular Graft Market?
The Vascular Graft Market covers synthetic and biologic conduits used to bypass, replace, or reconstruct diseased arterial and venous segments in peripheral vascular, aortic, and coronary revascularization performed by vascular and cardiothoracic surgeons. Hospitals with dedicated vascular and cardiac surgery programs implant Vascular Graft products in patients with peripheral arterial disease, aortic aneurysm, and coronary artery disease when endovascular interventions cannot achieve durable revascularization. The market encompasses expanded polytetrafluoroethylene and polyester grafts for peripheral bypass and aortic reconstruction, cryopreserved arterial and venous allografts, heparin-bonded and silver-impregnated infection-resistant configurations, and tissue-engineered vascular grafts under clinical development for small-diameter arterial replacement. International Society for Vascular Surgery and European Society for Vascular Surgery guidelines define clinical criteria governing graft selection and procedure timing.
2. Vascular Graft Market Size & Forecast
3. Emerging Technologies
- Expanded polytetrafluoroethylene vascular grafts provide a high-strength, blood-compatible synthetic conduit for peripheral arterial bypass, aortic reconstruction, and dialysis access in patients without suitable autologous vein conduit. Gore pioneered commercial ePTFE vascular grafts and continues to offer GORE-TEX and PROPATEN heparin-bonded lines as the clinical benchmark for synthetic peripheral bypass.
- Woven polyester grafts offer dimensional stability and high tensile strength for aortic tube and bifurcation reconstruction, withstanding high pulsatile aortic pressures over decades of implantation in infrarenal and thoracoabdominal aneurysm repair. LeMaitre Vascular, Getinge, and Terumo Aortic manufacture commercial polyester aortic grafts used in open surgical aortic reconstruction at cardiac and vascular surgery programs globally.
- Cryopreserved allograft conduits derived from donor arteries or veins provide an infection-resistant biological conduit for use in vascular graft infection salvage, mycotic aneurysm repair, and reconstruction in infected fields where synthetic graft explantation is required. CryoLife and AlloSource process and distribute cryopreserved vascular allografts for complex infected vascular reconstructions at academic centers.
- Tissue-engineered decellularized vascular constructs provide an off-the-shelf biological scaffold that recipient endothelial cells colonize after implantation, combining the availability of synthetic grafts with the biocompatibility of autologous conduits in small-diameter applications. Humacyte's human acellular vessel has demonstrated hemodialysis access patency in Phase 2 trials and is advancing through Phase 3 for FDA consideration.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Hernia Mesh Market.
4. Key Market Opportunity
One of the most substantial opportunities in the Vascular Graft Market is the growing demand for heparin-bonded and bioactive-surface synthetic grafts in peripheral bypass programs, where below-knee revascularization for limb salvage in diabetic and elderly patients with absent autologous vein conduit represents a large and growing surgical population. The development of tissue-engineered vascular grafts for small-diameter bypass and dialysis access represents a significant incremental opportunity, as successful commercial launch would address a clinical need currently unmet by existing synthetic products. Rising hemodialysis population growth globally, driven by increasing chronic kidney disease prevalence, generates consistent demand for dialysis access grafts as arteriovenous fistula failure requires graft-based access creation. As peripheral arterial disease prevalence increases with aging populations across North America, Europe, and Asia Pacific, surgical bypass volume is growing in patient subgroups not suitable for catheter-based revascularization.
5. Top Companies in the Vascular Graft Market
The following organisations hold leading positions in the Vascular Graft Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- W.L. Gore and Associates
- LeMaitre Vascular
- Getinge (Maquet Cardiovascular)
- Terumo Aortic
- CryoLife
- Humacyte
- Becton Dickinson (Bard Peripheral Vascular)
- Cook Medical
- Teleflex (Vascular Solutions)
- Braile Biomedica
6. Market Segmentation
The Vascular Graft Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Material | ePTFE Grafts Polyester Grafts Biologic Allografts Tissue-Engineered Grafts |
| By Application | Peripheral Arterial Bypass Aortic Reconstruction Dialysis Access Coronary Bypass |
| By End User | Hospitals and Vascular Surgery Centers Cardiac Surgery Hospitals |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Vascular Graft Market trajectory over the forecast period:
Heparin-Bonded Vascular Grafts Are Improving Primary Patency in Below-Knee Peripheral Bypass Surgery.Standard ePTFE grafts in below-knee peripheral bypass achieve inferior long-term patency compared to autologous vein, and heparin surface modification has been introduced to reduce early graft thrombosis by inhibiting platelet adhesion at the graft-blood interface. W.L. Gore's PROPATEN vascular graft featuring covalently bonded heparin has demonstrated improved primary patency at 12 and 24 months versus uncoated ePTFE in published multicenter studies of below-knee bypass. The clinical case for heparin-bonded grafts is strongest in patients lacking suitable autologous vein conduit, where synthetic graft performance is most critical for limb salvage outcomes. Regulatory approvals of heparin-bonded graft products in additional markets are supporting international commercial expansion of bioactive-surface vascular graft technology.
Endovascular Repair Is Reducing Open Aortic Surgery Volume but Driving Growth in Stent Graft Markets.The shift from open surgical to endovascular aortic aneurysm repair has reduced demand for traditional woven polyester tube grafts while generating significant growth in endovascular stent graft devices as the minimally invasive alternative. Medtronic reported consistent volume growth in its Endurant endovascular aneurysm repair stent graft system through 2023, with endovascular repair accounting for over 80 percent of infrarenal aortic aneurysm repairs at high-volume vascular centers. The endovascular shift has not eliminated open repair demand, as complex anatomical cases including juxtarenal and thoracoabdominal aneurysms still require conventional vascular graft products. Endovascular and open graft product segments remain co-dependent, with centers maintaining open repair capability as a safety net for cases requiring surgical conversion.
Tissue-Engineered Small-Diameter Vascular Grafts Are Advancing Through Clinical Trials for Below-Knee and Dialysis Access Applications.The failure of synthetic ePTFE grafts in small-diameter bypass applications below six millimeters has driven investment in tissue-engineered vascular constructs as potential off-the-shelf conduits for coronary and peripheral small-vessel bypass. Humacyte's human acellular vessel, composed of decellularized human smooth muscle cell-deposited extracellular matrix, received FDA breakthrough device designation and has been evaluated in Phase 3 trials for arteriovenous access in hemodialysis patients and peripheral arterial bypass. Successful clinical validation would represent a significant expansion of the addressable small-diameter graft market currently underserved by existing synthetic options. Commercial launch of tissue-engineered vascular grafts would drive a new premium segment in a market historically dominated by synthetic ePTFE and polyester materials.
For related market intelligence, see the Suture Market.
8. Segmental Analysis
By material, the ePTFE Grafts segment dominated the Vascular Graft Market in 2025, representing the primary synthetic graft category for peripheral arterial bypass and dialysis access creation at hospital vascular surgery programs, with heparin-bonded variants capturing a growing share of peripheral bypass revenue as below-knee revascularization volume grows. The Tissue-Engineered Vascular Grafts segment is the fastest-growing category, advancing from clinical trial status toward commercial launch as Humacyte and other developers demonstrate phase-advancing data supporting FDA regulatory submissions for dialysis access and peripheral bypass indications.
By application, Peripheral Arterial Bypass led overall market revenue, while Dialysis Access is registering the highest growth rate as global hemodialysis populations expand and arteriovenous fistula maturation failure sustains synthetic graft demand across nephrology programs.
9. Regional Analysis
Regional demand patterns across the Vascular Graft Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Vascular Graft Market in 2025, accounting for approximately ~44% of global market revenue, supported by high peripheral arterial disease surgical bypass volumes driven by large diabetic and elderly patient populations, established vascular surgery program infrastructure at academic and regional medical centers, and the commercial leadership of W.L. Gore in the ePTFE graft segment. Moreover, high end-stage renal disease prevalence generating consistent hemodialysis access graft demand and the active clinical trial infrastructure for tissue-engineered vascular graft development at US vascular centers sustain North American leadership across both commercial and advanced graft product segments. In addition, FDA regulatory engagement on breakthrough device designations for next-generation graft technologies accelerates clinical validation timelines and maintains a product development pipeline attracting commercial investment. The established clinical infrastructure, high procedure volumes, and product development leadership sustain North American dominance in the Vascular Graft Market through the forecast period.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Vascular Graft Market through 2034, advancing at approximately ~12.5%, driven by increasing prevalence of peripheral arterial disease, diabetes-related vascular complications, and end-stage renal disease across China, India, South Korea, and Japan, generating growing surgical bypass and dialysis access graft procedure volumes at tertiary and regional hospitals. The region benefits from expanding vascular and cardiac surgery training programs at major teaching hospitals, increasing the surgical workforce capable of performing open bypass procedures requiring synthetic and biologic graft products. Moreover, government health insurance coverage expansion for vascular surgery in China and South Korea is improving access for peripheral arterial disease patients who previously presented with advanced limb-threatening ischemia. The combination of chronic disease incidence growth, expanding surgical capacity, and government coverage expansion positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Vascular Graft Market was valued at USD 2.51 Bn in 2025 and is projected to reach USD 5.63 Bn by 2034, growing at a CAGR of 9.4% over the 2026–2034 forecast period.
The Vascular Graft Market is projected to grow at a CAGR of 9.4% from 2026 to 2034.
North America dominated the Vascular Graft Market in 2025, accounting for approximately ~44% of global market revenue, supported by high peripheral arterial disease surgical bypass volumes driven by large diabetic and elderly patient populations, established vascular surgery program infrastructure at academic and regional medical centers, and the commercial leadership of W.L.
The leading companies in the Vascular Graft Market include W.L. Gore and Associates, LeMaitre Vascular, Getinge (Maquet Cardiovascular), Terumo Aortic, CryoLife, Humacyte, Becton Dickinson (Bard Peripheral Vascular), Cook Medical, Teleflex (Vascular Solutions), Braile Biomedica.
Heparin-bonded vascular grafts are improving primary patency in below-knee peripheral bypass surgery.
By material, the ePTFE Grafts segment dominated the Vascular Graft Market in 2025, representing the primary synthetic graft category for peripheral arterial bypass and dialysis access creation at hospital vascular surgery programs, with heparin-bonded variants capturing a growing share of peripheral bypass revenue as below-knee revascularization volume grows.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.